Assura PLC (AGR.L), a prominent name in the UK’s real estate sector, stands at the forefront of healthcare-focused Real Estate Investment Trusts (REITs). With a market capitalization of $1.54 billion, Assura’s portfolio boasts over 600 healthcare facilities, catering to the needs of more than six million patients. As a constituent of the FTSE 250 and EPRA indices, Assura’s strategic positioning and commitment to environmental, social, and governance (ESG) principles have carved a robust identity in the investment landscape.
Currently trading at 47.48 GBp, Assura’s stock has shown resilience within its 52-week range of 35.34 to 50.65 GBp. Even as the stock price remains stable with negligible price change, the company offers an enticing dividend yield of 7.08%, complemented by a payout ratio of 63.40%. This steady income stream is a key attraction for income-focused investors, particularly in a sector known for its defensive characteristics.
Assura’s revenue growth of 24.30% underscores its robust financial health. The company’s earnings per share (EPS) stands at 0.05, with a commendable return on equity of 10.66%. These metrics reflect a well-managed operational framework, ensuring sustainable growth and profitability. However, the lack of a trailing P/E ratio and other valuation metrics such as PEG, Price/Book, and EV/EBITDA suggests that traditional valuation methods may not fully capture the company’s performance dynamics.
From an analyst perspective, the stock has one buy rating and three hold ratings, indicating a cautious yet optimistic outlook. The average target price of 49.67 GBp suggests a potential upside of 4.61%, aligning with the current market sentiment that leans towards stability rather than aggressive growth. The projected target price range of 48.00 to 51.00 GBp provides a narrow band, reflecting confidence in the stock’s near-term performance.
Technical indicators offer additional insights: Assura’s 50-day moving average is slightly higher at 47.93 GBp compared to the current price, while the 200-day moving average of 45.71 GBp suggests a longer-term uptrend. The Relative Strength Index (RSI) at 33.05 indicates the stock is nearing oversold conditions, which might pique the interest of investors looking for value opportunities. Meanwhile, the Moving Average Convergence Divergence (MACD) of -0.10, against a signal line of -0.30, suggests bearish momentum is waning.
Assura’s commitment to ESG principles and its status as the first FTSE 250 certified B Corp reflects a forward-thinking approach that appeals to socially responsible investors. Its merger with Primary Health Properties Plc as of September 2025 positions the company for enhanced strategic synergies, potentially unlocking further value.
For investors seeking a blend of stable income and capital appreciation in the real estate sector, particularly within the healthcare niche, Assura PLC presents a compelling case. Its strategic focus on healthcare infrastructure, coupled with a robust dividend yield and commitment to sustainable growth, positions it as a noteworthy consideration for portfolios emphasizing income and resilience in uncertain economic climates.
